4DMedical (ASX: 4DX) has expanded its partnership with University of Chicago Medicine to include commercial deployment of CT:VQ™, marking the fifth U.S. academic medical centre to adopt the respiratory imaging technology within under five months of FDA clearance. UChicago Medicine, ranked among the top U.S. hospitals for pulmonology and lung surgery, will integrate CT:VQ™ into its Interventional Pulmonology and Advanced Diagnostics programs alongside its existing use of 4DMedical’s structural and functional lung imaging products.
University of Chicago Medicine expands 4DMedical partnership with CT:VQ commercial deployment
The 4DMedical University of Chicago partnership builds on a long-standing relationship where UChicago Medicine has utilised 4DMedical’s comprehensive portfolio, including CT LVAS™, to support clinical decisions in COPD, small airways disease, and pre-procedural planning. The expanded agreement incorporates a renewed imaging analysis platform agreement and a commercial contract for CT:VQ™ with an initial prepaid scan package designed to accelerate clinical deployment.
UChicago Medicine becomes the fifth elite academic medical centre to adopt CT:VQ™ following FDA clearance, joining a prestigious cohort of institutions that demonstrates rapid market validation:
- Stanford University – Leading research institution with advanced pulmonary programs
- Cleveland Clinic – Nationally recognised cardiothoracic centre
- UC San Diego Health – Major West Coast academic medical facility
- University of Miami – Southeast regional respiratory care leader
- University of Chicago Medicine – Premier Midwest pulmonology centre
This rapid adoption by top-tier academic medical centres validates 4DMedical’s commercialisation strategy and strengthens its position with key opinion leaders who influence broader healthcare system adoption.
What is CT:VQ and why does it matter?
CT:VQ™ is 4DMedical’s respiratory imaging technology that combines ventilation and perfusion analysis from existing CT scans. The technology enables physicians to assess both how air flows through the lungs (ventilation) and how blood circulates through lung tissue (perfusion) using scans they are already ordering as part of standard clinical workflows.
The clinical workflow advantage is significant. CT:VQ™ extracts additional functional insights from CT scans physicians routinely order for respiratory patients, eliminating the need for separate imaging procedures. This approach reduces adoption friction and accelerates integration into established clinical pathways, as physicians can access enhanced diagnostic information without adding procedural steps or patient burden.
UChicago Medicine’s clinical applications and growth potential
UChicago Medicine’s Interventional Pulmonology and Advanced Diagnostics programs will deploy CT:VQ™ across multiple clinical applications, including complex lung disease assessment, COPD management, small airways disease evaluation, and pre-procedural planning for interventions. The institution has been an early adopter of functional imaging, using 4DMedical’s analyses to enhance understanding of regional ventilation and support clinical decision-making.
Professor Kyle Hogarth, Director of Bronchoscopy at UChicago Medicine, has emerged as a vocal advocate for advanced respiratory imaging across multiple investor webinars. His clinical perspective highlights how CT:VQ™ provides value in evaluating regional ventilation and perfusion for intervention planning and ongoing patient management.
Clinical Perspective
Professor Kyle Hogarth has spoken across multiple recent investor webinars about the clinical advantages CT:VQ™ provides in his practice, particularly its value in evaluating regional ventilation and perfusion for intervention planning and ongoing patient management, derived from CT scans he was already ordering as part of the care pathway.
While the initial prepaid scan package is not financially material to 4DMedical, UChicago Medicine represents an opinion-leading site with significant potential to scale CT:VQ™ utilisation as clinical workflows are established and procedural demand grows.
Commercial structure of the expanded agreement
The expanded arrangement comprises two components: a renewed imaging analysis platform agreement and a commercial contract for CT:VQ™ incorporating an initial package of prepaid scans. The prepaid model accelerates clinical deployment by enabling immediate integration into UChicago Medicine’s respiratory care pathways.
Building the reference site network
The five academic medical centre deployments achieved within five months of FDA clearance serve as strategic anchors for 4DMedical’s broader commercialisation strategy. These prestigious institutions function as validation platforms and key opinion leader sites that influence adoption decisions across the wider healthcare system.
| Academic Medical Centre | Regional Position | CT:VQ Status |
|---|---|---|
| Stanford University | West Coast research leader | Commercial deployment |
| Cleveland Clinic | National cardiothoracic centre | Commercial deployment |
| UC San Diego Health | Major West Coast AMC | Commercial deployment |
| University of Miami | Southeast respiratory leader | Commercial deployment |
| University of Chicago Medicine | Premier Midwest pulmonology | Commercial deployment |
Combined with 4DMedical’s partnership with Philips and a growing commercial pipeline, these reference sites position CT:VQ™ to establish a new standard of care in pulmonary imaging. Academic medical centres drive awareness and adoption across connected healthcare networks, with physicians at regional hospitals often following clinical practices established at leading institutions.
What comes next for 4DMedical
CEO Andreas Fouras highlighted the momentum building behind CT:VQ™ commercialisation, noting the rapid adoption by elite institutions demonstrates both the technology’s potential and the strength of 4DMedical’s go-to-market execution.
CEO Commentary
“In under five months since FDA clearance, we’ve now established CT:VQ™ at five of America’s leading academic medical centers: Stanford, University of Miami, Cleveland Clinic, UC San Diego Health, and University of Chicago Medicine. This rapid adoption by elite institutions demonstrates both the transformative potential of CT:VQ™ and the strength of our go-to-market execution. These prestigious AMCs serve as powerful anchors for our commercialisation strategy. Combined with our Philips partnership and growing commercial pipeline, we are building unstoppable momentum as we establish CT:VQ™ as the new standard of care in pulmonary imaging. The momentum continues to build, and I look forward to sharing further progress with shareholders as we advance through 2026.”
The consistent stream of academic medical centre wins demonstrates execution capability and supports the thesis that CT:VQ™ can scale commercially across the U.S. healthcare system. As clinical workflows are established at these reference sites and procedural demand grows, 4DMedical is positioned to expand deployment across broader hospital networks where opinion leaders at academic medical centres influence technology adoption decisions.
Want more Biotech breakthroughs like this?
4DMedical’s rapid expansion across five elite U.S. academic medical centres demonstrates the type of clinical validation that often precedes significant commercial acceleration in the Biotech sector. These pivotal developments don’t happen in isolation—they’re part of broader sector trends shaping investment opportunities across ASX-listed Healthcare and Biotech stocks.
StockWire X delivers FREE breaking news and in-depth analysis covering exactly these types of developments across Tech, Biotech, Healthcare, Finance, and Industrial sectors. Join 20,000+ investors who receive Big News Blasts the moment significant announcements hit the market. Click the ‘Free Alerts’ button in the menu above to ensure you never miss the next major Biotech catalyst or sector-moving development.